Bain Company

Third, there is the question of how unfair current price differentials in the global pharmaceutical market actually are. The authors of the previously cited Bain study proposed that Europeans should pay prices proportional to their GDP per capita (Bain Company 2005, p. 5). That idea has been echoed by most critics of the current, allegedly free rider system. There is evidence that, by and large, this criterion is actually being met. 

Bain Company. 2005. The Pharma Innovation Divide The High Cost of Europe s Free Ride. Available at www.bain.com/bainweb/Consulting Experhse/hot topics/ detaU.asp id=22. Last accessed October 28, 2005. 

Gilbert, G. and P. Rosenberg. 2004. Addressing the Innovation Divide Imbalanced Innovation. Munich, Germany Bain Company. Available at http //www.bain.com/bainweb/PDFs/ cms/Marketing/addressing innovation divide.pdf [Accessed December 17, 2005]. 

Research and Manufacturers of America (PliRMA) (9/10) is 799 million, and a report by Bain Company (11) estimates the cost for a new drug at 1.7 billion. These cost estimates take the following factors into consideration ... 

Bains Company Reports. Rebuilding Big Pharma s Business Model. (2003) Addressing the Innovation Divide Imbalanced innovation (2004). 

In the late 1990s in the United States, many companies mshed to implement CRM applications. Three consultants from the consulting firm Bain Company describe their research into outcomes from these efforts." Their decision to pursue this line of research came from the CRM s low ratings in Bain s 2001 survey of management tools, in which CRM was third from the bottom of the 25 tools evaluated. They report that one manufacturer scrapped a 30-million investment in the technology. 

A variety of enameled-steel pots known as bain-marie is available from the American Specialty Company, Rochester, New York. 

Bain, L. J. Engelhardt, M. 1992. Introduction to Probability and Mathematical Statistics, 2nd Edition. Boston, Mossachusett PWSKENT Publishing Company. 

---